Restoration by aspirin of impaired plasma maspin level in human breast cancer

Maspin, an anti breast cancer protein, is produced in the normal mammary cells but not in malignant cells in breast cancer. We investigated the effect of aspirin induced increase of plasma nitric oxide (NO) on plasma maspin production in breast cancer patients. Fifteen breast cancer patients (35-65 years), who had not yet undergone any cancer therapy, and an equal number of age matched normal female volunteers participated in the study. They were asked not to take any medication for two weeks. All participants then ingested 150 mg of aspirin. Plasma NO and maspin levels were determined before and at 60 min after the ingestion of aspirin. It was found that the maspin level in plasma increased to 4.63±0.02 nM from the basal 0.95±0.012 nM (p <0.001) with increase of plasma NO from 0.60±0.03 μM to 2.08±0.030 μM (p <0.001) in breast cancer patients. In normal volunteers the basal maspin increased from 4.76±0.041 to 9.36±0.036 nM (p <0.001) with increase of NO from 2.15±0.08 to 3.36±0.04 μM (p <0.001) at the same period. These results indicated that the ingestion of aspirin might be beneficial for breast cancer through increased maspin production.